Publicacions en col·laboració amb investigadors/es de Eli Lilly and Company (13)

2023

  1. Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes

    Diabetes Therapy, Vol. 14, Núm. 11, pp. 1771-1784

2022

  1. Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study

    Journal of Headache and Pain, Vol. 23, Núm. 1

2021

  1. Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm

    Advances in Therapy, Vol. 38, Núm. 8, pp. 4442-4460

2019

  1. Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

    European Journal of Cancer, Vol. 107, pp. 186-195

  2. Transforming Breast Cancer Together: European elections manifesto 2019 seizing the opportunities for breast cancer patients

    Breast

2016

  1. Immunodynamics: A cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

    Journal for ImmunoTherapy of Cancer, Vol. 4, Núm. 1

2013

  1. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck

    European Journal of Cancer, Vol. 49, Núm. 13, pp. 2877-2883

2006

  1. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer

    International Journal of Gynecological Cancer, Vol. 16, Núm. 1, pp. 71-76

2005

  1. Assessment of the value of confirming responses in clinical trials in oncology

    European Journal of Cancer, Vol. 41, Núm. 11, pp. 1528-1532

  2. Seguridad y eficacia de la atomoxetina en niños con trastorno por déficit de atención/hiperactividad (TDAH): Fase inicial durante 10 semanas en estudio de prevención de recaídas en una muestra española

    Actas Espanolas de Psiquiatria, Vol. 33, Núm. 1, pp. 26-32

2002

  1. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: Systematic review of the literature and implications for future research

    Gynecologic Oncology, Vol. 84, Núm. 2, pp. 201-209

  2. The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research

    Cancer, Vol. 95, Núm. 7, pp. 1605-1610

1998

  1. Human osteoblasts express a repertoire of cadherins, which are critical for BMP-2-induced osteogenic differentiation

    Journal of Bone and Mineral Research, Vol. 13, Núm. 4, pp. 633-644